JNJ · Forward model · Other Innovative Medicine
What has to happen in Other Innovative Medicine
Model as of
This page changes Other Innovative Medicine inside the complete JNJ model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
Other Innovative Medicine
Basis quarter$2.80B
Final quarter$2.94B
Implied CAGR+1%
Final revenue mix9%
Pulmonary hypertension, infectious diseases and cardiovascular/metabolism/other - a roughly flat $2.8-2.9B a quarter tail around XARELTO, UPTRAVI, OPSUMIT and the HIV portfolio.
Last four quarters
2025 Q3
$2.84B
Reported
2025 Q4
$2.93B
Reported
2026 Q1
$2.90B
Reported
2026 Q2
$2.80B
Reported
Pulmonary hypertension (UPTRAVI, OPSUMIT/OPSYNVI)Infectious diseases (PREZISTA, EDURANT)XARELTOOther
Sequential growth
+0.2%/qtr
decaying toward +0.3%
0.2% a quarter: this tail printed -1.7% year over year and +1.2% TTM, flat within noise.
Other Innovative Medicine
Latest: $2.94B (2031Q2E)
| Period | Value |
|---|---|
| 2023Q1 | $3.38B |
| 2023Q2 | $3.04B |
| 2023Q3 | $2.77B |
| 2023Q4 | $2.71B |
| 2024Q1 | $2.70B |
| 2024Q2 | $2.90B |
| 2024Q3 | $2.82B |
| 2024Q4 | $2.82B |
| 2025Q1 | $2.84B |
| 2025Q2 | $2.85B |
| 2025Q3 | $2.84B |
| 2025Q4 | $2.93B |
| 2026Q1 | $2.90B |
| 2026Q2 | $2.80B |
| 2026Q3E | $2.80B |
| 2026Q4E | $2.81B |
| 2027Q1E | $2.81B |
| 2027Q2E | $2.82B |
| 2027Q3E | $2.83B |
| 2027Q4E | $2.83B |
| 2028Q1E | $2.84B |
| 2028Q2E | $2.85B |
| 2028Q3E | $2.86B |
| 2028Q4E | $2.86B |
| 2029Q1E | $2.87B |
| 2029Q2E | $2.88B |
| 2029Q3E | $2.89B |
| 2029Q4E | $2.89B |
| 2030Q1E | $2.90B |
| 2030Q2E | $2.91B |
| 2030Q3E | $2.92B |
| 2030Q4E | $2.93B |
| 2031Q1E | $2.94B |
| 2031Q2E | $2.94B |
Assumptions & reasoning
- This line is the only apportioned figure in the model: Innovative Medicine total less Oncology, Immunology and Neuroscience. It cross-checks to J&J's separately printed TOTAL PH, ID, CVM subtotal within $2M in all fourteen quarters, so it is a subtraction of disclosed numbers rather than an estimate.
- Pulmonary hypertension, infectious disease and cardiovascular and metabolism: XARELTO, UPTRAVI, OPSUMIT and the HIV book, running $2.8-2.9B a quarter for eight quarters. Left aseasonal because the 3.5% amplitude is inside a 4.7% window spread.